Clinical Trials Logo

Vestibular Schwannoma clinical trials

View clinical trials related to Vestibular Schwannoma.

Filter by:

NCT ID: NCT03210285 Completed - Clinical trials for Vestibular Schwannoma

WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

NF2
Start date: July 31, 2017
Phase:
Study type: Observational [Patient Registry]

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

NCT ID: NCT03097822 Not yet recruiting - Clinical trials for Vestibular Schwannoma

Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging

Start date: January 2017
Phase: N/A
Study type: Observational

Response Prediction after Gamma Knife Surgery (GKS) in Patients with Vestibular Schwannoma using Dynamic Contrast-Enhanced (DCE) MR Imaging

NCT ID: NCT03095248 Active, not recruiting - Glioma Clinical Trials

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

SEL-TH-1601
Start date: May 8, 2017
Phase: Phase 2
Study type: Interventional

In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor. The researchers are asking patients with NF2 related tumors to be in the study, because their hearing has decreased and/or their NF2 related tumor has started to grow. The goals of this study are: - Determine if selumetinib will stop NF2 related tumors from growing - Measure the changes in hearing after receiving selumetinib for 6 months. - Determine if selumetinib improves how participants feel (physically and emotionally) and how participants can perform daily activities. - Examine tumor tissue, if available, in a laboratory to see if NF2 related tumors have targets of selumetinib.

NCT ID: NCT03079999 Recruiting - Clinical trials for Vestibular Schwannoma

Study of Aspirin in Patients With Vestibular Schwannoma

Start date: June 11, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

NCT ID: NCT02963896 Completed - Clinical trials for Vestibular Schwannoma

Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma

ITG
Start date: January 2014
Phase: N/A
Study type: Interventional

Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo. Preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively.

NCT ID: NCT02934256 Completed - Clinical trials for Vestibular Schwannoma

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Icotinib
Start date: July 2016
Phase: Phase 2
Study type: Interventional

1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged randomized double-blind trial.

NCT ID: NCT02415257 Withdrawn - Clinical trials for Vestibular Schwannoma

Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function

Start date: April 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating vestibular function prior to surgery, even if vestibular function is absent according to modern assessment techniques

NCT ID: NCT02379754 Withdrawn - Clinical trials for Vestibular Schwannoma

Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function

Start date: January 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating remaining vestibular function prior to surgery, through gentamicin injections in the middle ear.

NCT ID: NCT02282917 Terminated - Meningioma Clinical Trials

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Start date: December 2015
Phase: Early Phase 1
Study type: Interventional

This will be a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in Vestibular Schwannoma (VS) and meningiomas by AR-42 in adult patients undergoing tumor resection. AR-42 is a small molecule which crosses the blood brain barrier (BBB) in rodents, but the investigators are not certain yet if it will penetrate human VS. Meningiomas are outside the BBB, but seem to be unusually resistant to all current medical treatments. The primary endpoint of the bioactivity of suppression of p-AKT by AR-42 was selected as drug activity seems more informative than bioavailability. Our preclinical data and others have shown dose dependent suppression of p-AKT by AR-42 in both VS and meningiomas.

NCT ID: NCT02275325 Recruiting - Clinical trials for Vestibular Schwannoma

Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery

ReveSTAN
Start date: January 2015
Phase: N/A
Study type: Interventional

Vestibular schwannoma (VS) is a benign tumour from Schwann cells surrounding the vestibular nerve, which slowly grows within the internal auditory canal and then into the cerebellopontine angle, leading to a gradual vestibular dysfunction. The slowly progressive alteration of vestibular function allows the gradual implementation of central adaptive mechanisms called vestibular compensation. The total unilateral vestibular deafferentation induced by the surgical tumour removal suddenly leads to a decompensation of this previously compensated situation, which explains why most patients report severe vertigo immediately after surgery and which is responsible for perturbations of the postural control (Parietti-Winkler et al., 2006, 2008, 2010, 2011). Recently, Gauchard et al. (2013) suggested that preoperative and regular physical activity would limit the adverse effects of surgical removal on balance control. Also, patients benefited faster and better from the postoperative vestibular rehabilitation. Thus, preoperative vestibular rehabilitation, including physical and balance exercises, could help to limit postoperative balance disorders and promote postoperative balance compensation. This could lead to a decrease in the duration and cost of the postoperative management and faster improvement of quality of life.